A 22-year-old woman presented with fatigue and leukocytosis without organomegaly and a referral diagnosis of chronic myeloproliferative neoplasm without BCR::ABL1 translocation or JAK2 mutation. Complete blood count showed leukocytosis (white blood cell [WBC], 21.8 × 109/L), anemia (hemoglobin, 11.1 gm/dL), and thrombocytopenia (platelets, 114 × 109/L) with neutrophilia (15.9 × 109/L), eosinophilia (1.74 × 109/L), and rare circulating blasts. Bone marrow (BM) biopsy was hypercellular (∼100%) with myeloid hyperplasia, atypical megakaryocytic hyperplasia, and clusters of foamy histiocytes (panel A, ×400, hematoxylin-eosin stain) highlighted with periodic acid–Schiff stain with fast green counterstain (panel B, ×400). BM smears showed left-shifted myeloid hyperplasia with numerous pseudo-Gaucher cells/sea blue histiocytes with abundant blue and variably lamellar cytoplasm (panel C; ×1000, Wright-Giemsa). Karyotyping detected a t(5;12) (panel D), and fluorescence in situ hybridization confirmed the presence of PDGFRB (panel E) and ETV6 rearrangement in 78% of analyzed cells. The patient was treated with imatinib (400 mg daily) and achieved remission with a WBC of 8.9 × 109/L at 1-month follow-up.
Sea-blue histiocytes and pseudo-Gaucher cells are a hallmark of increased cell turnover and characteristically associated with chronic myeloid leukemia BCR::ABL1+. To our knowledge, this is the first report describing increased pseudo-Gaucher cells in association with a myeloid neoplasm with eosinophilia and PDGFRB rearrangement, expanding the spectrum of this morphologic finding.
A 22-year-old woman presented with fatigue and leukocytosis without organomegaly and a referral diagnosis of chronic myeloproliferative neoplasm without BCR::ABL1 translocation or JAK2 mutation. Complete blood count showed leukocytosis (white blood cell [WBC], 21.8 × 109/L), anemia (hemoglobin, 11.1 gm/dL), and thrombocytopenia (platelets, 114 × 109/L) with neutrophilia (15.9 × 109/L), eosinophilia (1.74 × 109/L), and rare circulating blasts. Bone marrow (BM) biopsy was hypercellular (∼100%) with myeloid hyperplasia, atypical megakaryocytic hyperplasia, and clusters of foamy histiocytes (panel A, ×400, hematoxylin-eosin stain) highlighted with periodic acid–Schiff stain with fast green counterstain (panel B, ×400). BM smears showed left-shifted myeloid hyperplasia with numerous pseudo-Gaucher cells/sea blue histiocytes with abundant blue and variably lamellar cytoplasm (panel C; ×1000, Wright-Giemsa). Karyotyping detected a t(5;12) (panel D), and fluorescence in situ hybridization confirmed the presence of PDGFRB (panel E) and ETV6 rearrangement in 78% of analyzed cells. The patient was treated with imatinib (400 mg daily) and achieved remission with a WBC of 8.9 × 109/L at 1-month follow-up.
Sea-blue histiocytes and pseudo-Gaucher cells are a hallmark of increased cell turnover and characteristically associated with chronic myeloid leukemia BCR::ABL1+. To our knowledge, this is the first report describing increased pseudo-Gaucher cells in association with a myeloid neoplasm with eosinophilia and PDGFRB rearrangement, expanding the spectrum of this morphologic finding.
For additional images, visit the ASH Image Bank, a reference and teaching tool that is continually updated with new atlas and case study images. For more information, visit http://imagebank.hematology.org.
![A 22-year-old woman presented with fatigue and leukocytosis without organomegaly and a referral diagnosis of chronic myeloproliferative neoplasm without BCR::ABL1 translocation or JAK2 mutation. Complete blood count showed leukocytosis (white blood cell [WBC], 21.8 × 109/L), anemia (hemoglobin, 11.1 gm/dL), and thrombocytopenia (platelets, 114 × 109/L) with neutrophilia (15.9 × 109/L), eosinophilia (1.74 × 109/L), and rare circulating blasts. Bone marrow (BM) biopsy was hypercellular (∼100%) with myeloid hyperplasia, atypical megakaryocytic hyperplasia, and clusters of foamy histiocytes (panel A, ×400, hematoxylin-eosin stain) highlighted with periodic acid–Schiff stain with fast green counterstain (panel B, ×400). BM smears showed left-shifted myeloid hyperplasia with numerous pseudo-Gaucher cells/sea blue histiocytes with abundant blue and variably lamellar cytoplasm (panel C; ×1000, Wright-Giemsa). Karyotyping detected a t(5;12) (panel D), and fluorescence in situ hybridization confirmed the presence of PDGFRB (panel E) and ETV6 rearrangement in 78% of analyzed cells. The patient was treated with imatinib (400 mg daily) and achieved remission with a WBC of 8.9 × 109/L at 1-month follow-up.](https://ash.silverchair-cdn.com/ash/content_public/journal/blood/140/6/10.1182_blood.2022016602/3/m_bloodbld2022016602f1.png?Expires=1768905335&Signature=HT~V67g49BV5y4ZlaNUsxly~hxvl26WG4~oMeJ2lRQKdTWU24D9DsxPtDRkbd~riZ6-xe1mVGGm1pIzmNgE~XNKxE415J-iy0hFQuI-VstWRzeXi6HzSjPWgox0KDLMBEuAvwZndvpOXGFZuZVEFgKUGxs0FJdz3lvmNTSc4Cl0EWbbvQk71HVCcbLg~zRZr2h9hVFPFijWXWbcEnegp7azmTDQZQ1iTR6jzm1gs1aFymK79zrUnpB03wu7WrE5ZcRenewuTVg1RI-t-xu4bPEs7C5GB6ef7jRvLuooWAz0Y0mdsJaN~avsfdKGXhmEB-oe3GnCyN1UrexAVXX-9Ag__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
![A 22-year-old woman presented with fatigue and leukocytosis without organomegaly and a referral diagnosis of chronic myeloproliferative neoplasm without BCR::ABL1 translocation or JAK2 mutation. Complete blood count showed leukocytosis (white blood cell [WBC], 21.8 × 109/L), anemia (hemoglobin, 11.1 gm/dL), and thrombocytopenia (platelets, 114 × 109/L) with neutrophilia (15.9 × 109/L), eosinophilia (1.74 × 109/L), and rare circulating blasts. Bone marrow (BM) biopsy was hypercellular (∼100%) with myeloid hyperplasia, atypical megakaryocytic hyperplasia, and clusters of foamy histiocytes (panel A, ×400, hematoxylin-eosin stain) highlighted with periodic acid–Schiff stain with fast green counterstain (panel B, ×400). BM smears showed left-shifted myeloid hyperplasia with numerous pseudo-Gaucher cells/sea blue histiocytes with abundant blue and variably lamellar cytoplasm (panel C; ×1000, Wright-Giemsa). Karyotyping detected a t(5;12) (panel D), and fluorescence in situ hybridization confirmed the presence of PDGFRB (panel E) and ETV6 rearrangement in 78% of analyzed cells. The patient was treated with imatinib (400 mg daily) and achieved remission with a WBC of 8.9 × 109/L at 1-month follow-up.](https://ash.silverchair-cdn.com/ash/content_public/journal/blood/140/6/10.1182_blood.2022016602/3/m_bloodbld2022016602f1.png?Expires=1768905336&Signature=3J5NWs~8YHddB0m1ZrM5tc2dRZy1JlNpQFjfBIf85LtPoVS43ZlR9CuiWRQt8ZBSjbDb2x8ZhGmBHtBRk2-j3bj8DJ7jR35pF-i4idogBv5fWucaXiU5g85m~3GQBkkTcdG2fTK55MYnwgFJjZvumRfJ90k9QSIsgKMxYXxc7lja-Oj3wYUah~AGuBWjhcDA-sNBohXvBD2N11Si16wD-vsPtLU8ZsPUjl6UfnxQwCUNItUgyDmhMsjEWc3QTtdaJGDaoOtlsRQmQD5aGgjuxmycFdFeu~1a~lnX2DLqxUz7Vr-66shNP3jb3h9~OqNUn36qxvF9QcBJ1ByiDCIZ~Q__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)